Flexible Microneedle Array Electrode with Improved Comfort, Low Impedance, and High Performance for Electrophysiological Recording
Wu et al.
The finding, in our words
The flexible microneedle array electrode achieved contact impedance one to two orders of magnitude lower than commercial wet electrodes, with 41 to 46 per cent higher signal amplitudes, better signal-to-noise ratio, and improved stability in human electrophysiological recordings, suggesting it could enable more comfortable long-term wearable monitoring.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The study observed favourable trends in the accrual of participants residing far from the site and those from underrepresented groups following the implementation of a decentralised clinical trial program.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.
This study demonstrates that a memristor sensor can identify distinct electrical signatures in saliva and urine corresponding to different ovulation phases, suggesting a potential route for noninvasive home fertility monitoring.
Menstrual blood offers a noninvasive, patient-centric matrix for detecting endometriosis, cervical cancer, and hormonal disorders through self-collected samples. Wearable in-pad biosensors enabling real-time monitoring and long-term tracking could transform fertility evaluation and early disease detection, though standardisation and large-scale validation remain critical gaps.
Shafiq et al., Annals of medicine and surgery · source ↗
A fully remote decentralised clinical trial in Danish adults with type 2 diabetes demonstrated operational feasibility with rapid recruitment, high retention (87 percent), and excellent adherence to continuous glucose monitoring (95 percent achieving ≥70 percent data coverage) and telemedicine visits (97 percent). Activity tracker adherence was poor (12 percent) due to technical issues, but remote safety monitoring was effective with no unexpected adverse events, supporting the viability of remote diabetes management.